{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:38:21Z","timestamp":1791873501048,"version":"4.3.4"},"reference-count":143,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>More than 97% of patients with acute myeloid leukemia (AML) demonstrate genetic mutations leading to excessive proliferation combined with the evasion of regulated cell death (RCD). The most prominent and well-defined form of RCD is apoptosis, which serves as a defense mechanism against the emergence of cancer cells. Apoptosis is regulated in part by the BCL-2 family of pro- and anti-apoptotic proteins, whose balance can significantly determine cell survival. Apoptosis evasion plays a key role in tumorigenesis and drug resistance, and thus in the development and progression of AML. Research on the structural and biochemical aspects of apoptosis proteins and their regulators offers promise for new classes of targeted therapies and strategies for therapeutic intervention. This review provides a comprehensive overview of current AML treatment options related to the mechanism of apoptosis, particularly its mitochondrial pathway, and other promising concepts such as neddylation. It pays particular attention to clinically-relevant aspects of current and future AML treatment approaches, highlighting the molecular basis of individual therapies.<\/jats:p>","DOI":"10.3390\/cancers14204995","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T20:53:29Z","timestamp":1665608009000},"page":"4995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting Apoptosis in AML: Where Do We Stand?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-7963","authenticated-orcid":false,"given":"Kinga","family":"Krawiec","sequence":"first","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-513 Lodz, Poland"},{"name":"Copernicus Multi-Specialist Oncology and Traumatology Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Strza\u0142ka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-513 Lodz, Poland"},{"name":"Copernicus Multi-Specialist Oncology and Traumatology Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-4662","authenticated-orcid":false,"given":"Magdalena","family":"Czemerska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-513 Lodz, Poland"},{"name":"Copernicus Multi-Specialist Oncology and Traumatology Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Wi\u015bnik","sequence":"additional","affiliation":[{"name":"Copernicus Multi-Specialist Oncology and Traumatology Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Zawlik","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, 35-310 Rzeszow, Poland"},{"name":"Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, College of Medical Sciences, University of Rzeszow, 35-310 Rzeszow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-513 Lodz, Poland"},{"name":"Copernicus Multi-Specialist Oncology and Traumatology Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-7452","authenticated-orcid":false,"given":"Agnieszka","family":"Pluta","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-513 Lodz, Poland"},{"name":"Copernicus Multi-Specialist Oncology and Traumatology Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Halik, A., Arends, C.M., Bullinger, L., Damm, F., and Frick, M. (2022). Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. Cancers, 14.","DOI":"10.3390\/cancers14071689"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Eng. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"634690","DOI":"10.3389\/fcell.2021.634690","article-title":"Guidelines for Regulated Cell Death Assays: A Systematic Summary, A Categorical Comparison, A Prospective","volume":"9","author":"Hu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","article-title":"Regulated cell death (RCD) in cancer: Key pathways and targeted therapies","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbamcr.2010.10.010","article-title":"Anti-apoptosis and cell survival: A review","volume":"1813","author":"Portt","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The rise of apoptosis: Targeting apoptosis in hematologic malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3324\/haematol.10279","article-title":"Deregulation of apoptosis in acute myeloid leukemia","volume":"92","author":"Testa","year":"2007","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12118","DOI":"10.1073\/pnas.1810017115","article-title":"Intracellular transport is accelerated in early apoptotic cells","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tcb.2013.07.006","article-title":"Evading apoptosis in cancer","volume":"23","author":"Fernald","year":"2013","journal-title":"Trends Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.21873\/anticanres.14622","article-title":"Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review","volume":"40","author":"Kontomanolis","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-cancerbio-050216-121933","article-title":"Apoptosis and Cancer","volume":"1","author":"Letai","year":"2017","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/2159-8290.CD-20-0789","article-title":"Modes of Regulated Cell Death in Cancer","volume":"11","author":"Koren","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-1-4614-3229-6_4","article-title":"Death by Caspase Dimerization","volume":"Volume 747","author":"MacKenzie","year":"2012","journal-title":"Protein Dimerization and Oligomerization in Biology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cdd.2011.96","article-title":"Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012","volume":"19","author":"Galluzzi","year":"2012","journal-title":"Cell Death Differ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118688","DOI":"10.1016\/j.bbamcr.2020.118688","article-title":"Targeting apoptotic caspases in cancer","volume":"1867","author":"Boice","year":"2020","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1515\/bmc-2016-0015","article-title":"Bcl-2 family proteins: Master regulators of cell survival","volume":"7","author":"Hatok","year":"2016","journal-title":"Biomol. Concepts"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and Clearance of Apoptotic Cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cgt.2012.84","article-title":"A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia","volume":"20","author":"Zhang","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/bjc.2017.281","article-title":"Targeting apoptosis in acute myeloid leukaemia","volume":"117","author":"Cassier","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Toufektchan, E., and Toledo, F. (2018). The Guardian of the Genome Revisited: P53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure. Cancers, 10.","DOI":"10.3390\/cancers10050135"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1038\/sj.onc.1205327","article-title":"Dysregulation of apoptosis genes in hematopoietic malignancies","volume":"21","author":"Kitada","year":"2002","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pfeffer, C.M., and Singh, A.T.K. (2018). Apoptosis: A Target for Anticancer Therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020448"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PPO.0000000000000569","article-title":"What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?","volume":"28","author":"Wang","year":"2022","journal-title":"Cancer J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 mutations in De Novo acute myeloid leukemia patients: Longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/gcc.22796","article-title":"The role of TP53 in acute myeloid leukemia: Challenges and opportunities","volume":"58","author":"Barbosa","year":"2019","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Shallis, R.M., Bewersdorf, J.P., Stahl, M.F., Halene, S., and Zeidan, A.M. (2022). Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?. Cancers, 14.","DOI":"10.3390\/cancers14102434"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13000-021-01162-8","article-title":"TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"16","author":"Niparuck","year":"2021","journal-title":"Diagn. Pathol."},{"key":"ref_34","first-page":"1296","article-title":"P53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status","volume":"31","author":"Hu","year":"2016","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J. Biomed. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics","volume":"9","author":"Jan","year":"2019","journal-title":"Adv. Pharm. Bull."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41435-019-0078-8","article-title":"Inhibitor of apoptosis proteins in human health and disease","volume":"20","author":"Hrdinka","year":"2019","journal-title":"Genes Immun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12929-020-0627-5","article-title":"Anti-apoptotic proteins in the autophagic world: An update on functions of XIAP, Survivin and BRUCE","volume":"27","author":"Cheung","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1038\/cddis.2013.311","article-title":"IAPs on the move: Role of inhibitors of apoptosis proteins in cell migration","volume":"4","author":"Murali","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3109\/10428194.2014.1003052","article-title":"Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia","volume":"56","author":"Pluta","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","article-title":"Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)","volume":"22","author":"Rathore","year":"2017","journal-title":"Apoptosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.2147\/OTT.S171053","article-title":"Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer","volume":"11","author":"Zhang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-9966-27-48","article-title":"Role of Smac\/DIABLO in cancer progression","volume":"27","author":"Maldonado","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.bpj.2014.11.3471","article-title":"The Activator of Apoptosis Smac-DIABLO Acts as a Tetramer in Solution","volume":"108","author":"Mastrangelo","year":"2015","journal-title":"Biophys. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"180002","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008255511404","article-title":"High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia","volume":"9","author":"Karakas","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.4081\/hr.2011.e28","article-title":"Clinical Significance of P53 and Bcl-2 in Acute Myeloid Leukemia Patients of Eastern India","volume":"3","author":"Sahu","year":"2011","journal-title":"Hematol. Rep."},{"key":"ref_48","first-page":"141","article-title":"High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"49","author":"Fricova","year":"2002","journal-title":"Neoplasma"},{"key":"ref_49","first-page":"1758","article-title":"The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics","volume":"5","author":"Kornblau","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13000-019-0841-1","article-title":"BCL2 overexpression: Clinical implication and biological insights in acute myeloid leukemia","volume":"14","author":"Zhou","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.14712\/fb2010056020051","article-title":"CCAAT\/enhancer-binding protein alpha (CEBPA) polymorphisms and mutations in healthy individuals and in patients with peripheral artery disease, ischaemic heart disease and hyperlipidaemia","volume":"56","author":"Fuchs","year":"2010","journal-title":"Folia Biol. (Praha)"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e8424","DOI":"10.1590\/1414-431x20198424","article-title":"CCAAT\/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM\/AF10 transgenic mice","volume":"52","author":"Lange","year":"2019","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_53","first-page":"470","article-title":"The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia","volume":"86","author":"Schaich","year":"2001","journal-title":"Haematologica"},{"key":"ref_54","first-page":"1","article-title":"Prognostic value of Bcl2-associated X protein (Bax) expression in adult Egyptian patients with acute myeloid leukemia","volume":"3","author":"Bekhet","year":"2016","journal-title":"Indian J. Med. Res. Pharm. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/sj.leu.2402340","article-title":"High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML)","volume":"16","author":"Schill","year":"2002","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"584974","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting Bcl-2 Proteins in Acute Myeloid Leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1158\/0008-5472.CAN-04-2263","article-title":"The FLT3 Internal Tandem Duplication Mutation Prevents Apoptosis in Interleukin-3-Deprived BaF3 Cells Due to Protein Kinase A and Ribosomal S6 Kinase 1\u2013Mediated BAD Phosphorylation at Serine 112","volume":"65","author":"Yang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2141.2006.06225.x","article-title":"Constitutively activated FLT3 phosphorylates BAD partially through Pim-1","volume":"134","author":"Kim","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD\u2013specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/OTT.S194549","article-title":"Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia","volume":"12","author":"Li","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000500822","article-title":"Expression and Relationship of SAMHD1 with Other Apoptotic and Autophagic Genes in Acute Myeloid Leukemia Patients","volume":"143","author":"Jiang","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"610820","DOI":"10.3389\/fonc.2020.610820","article-title":"TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?","volume":"10","author":"Molica","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_65","first-page":"e1178","article-title":"The Expression of the Tp53 Gene in Various Classes of Acute Myeloid Leukemia","volume":"5","author":"Ahmadzadeh","year":"2018","journal-title":"World Cancer Res. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7123\/01.EJH.0000428063.29317.e1","article-title":"SMAC\/DIABLO gene expression in acute myeloid leukemia patients","volume":"38","author":"Suliman","year":"2013","journal-title":"Egypt. J. Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"700","DOI":"10.5114\/aoms.2019.89918","article-title":"The role of NF-\u03baB and Smac\/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients","volume":"17","author":"Pluta","year":"2021","journal-title":"Arch. Med. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S2152-2650(20)30464-X","article-title":"Harnessing Apoptosis in AML","volume":"20","author":"Saxena","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2018","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: Changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3+7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: A multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: The next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e1590","DOI":"10.1038\/cddis.2014.561","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6","author":"Leverson","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41419-021-03500-6","article-title":"The application of BH3 mimetics in myeloid leukemias","volume":"12","author":"Parry","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"564108","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent","volume":"11","author":"Anuar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41420-020-00348-1","article-title":"BCL-XL is an actionable target for treatment of malignant pleural mesothelioma","volume":"6","author":"Arulananda","year":"2020","journal-title":"Cell Death Discov."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1871529X21666210308111546","article-title":"Preclinical Studies of PROTACs in Hematological Malignancies","volume":"21","author":"Fuchs","year":"2021","journal-title":"Cardiovasc. Hematol. Disord. Targets"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2021-147535","article-title":"Targeting BCL-XL and BCL-2 by Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy by Targeting Senescent Cells","volume":"138","author":"Jia","year":"2021","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1021\/acs.jmedchem.1c00996","article-title":"Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells","volume":"64","author":"Cao","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood-2021-152618","article-title":"Therapy-Induced Senescence as an Anti-Cancer and Immune-Stimulatory Strategy","volume":"138","author":"Gilioli","year":"2021","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1039\/D1CB00011J","article-title":"Proteolysis targeting chimeras (PROTACs) come of age: Entering the third decade of targeted protein degradation","volume":"2","author":"Bond","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood-2021-147482","article-title":"NIMBLE: A Phase I\/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies","volume":"138","author":"Konopleva","year":"2021","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: Current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Sancho, M., Leiva, D., Lucendo, E., and Orz\u00e1ez, M. (2021). Understanding MCL1: From cellular function and regulation to pharmacological inhibition. FEBS J.","DOI":"10.1111\/febs.16136"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1517\/13543784.2011.609167","article-title":"Targeting Mcl-1 for the therapy of cancer","volume":"20","author":"Quinn","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2015.125849","article-title":"Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine and mitoxantrone (FLAM) versus cytarabine\/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia","volume":"100","author":"Zeidner","year":"2015","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-20-2649","article-title":"Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia","volume":"27","author":"Zeidner","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Cetraro, P., Plaza-Diaz, J., MacKenzie, A., and Abad\u00eda-Molina, F. (2022). A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer. Cancers, 14.","DOI":"10.3390\/cancers14071671"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/17474086.2020.1852923","article-title":"Apoptosis targeted therapies in acute myeloid leukemia: An update","volume":"13","author":"Ball","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2011.03.033","article-title":"Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients with Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study","volume":"11","author":"Schimmer","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-19-1430","article-title":"A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma","volume":"26","author":"Mita","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: A unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10637-013-9935-x","article-title":"Safety and Pharmacokinetics of the Antisense Oligonucleotide (ASO) LY2181308 as a Single-Agent or in Combination with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML)","volume":"31","author":"Erba","year":"2013","journal-title":"Investig. N. Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/14712598.2021.1918672","article-title":"Survivin as a biological biomarker for diagnosis and therapy","volume":"21","author":"Li","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood.V124.21.3758.3758","article-title":"A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia","volume":"124","author":"Frey","year":"2014","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chang, Y.-C., and Cheung, C.H.A. (2020). An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment. Appl. Sci., 11.","DOI":"10.3390\/app11010335"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"George, B., Kantarjian, H., Baran, N., Krocker, J.D., and Rios, A. (2021). TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910782"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1126\/sciadv.abm9427","article-title":"Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction","volume":"8","author":"Fujihara","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2021-147962","article-title":"Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)","volume":"138","author":"Mishra","year":"2021","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2021-148940","article-title":"Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)","volume":"138","author":"Goldberg","year":"2021","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2021","journal-title":"Haematologica"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3324\/haematol.2019.218453","article-title":"Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Maslah","year":"2019","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_120","first-page":"5762","article-title":"Therapeutic opportunities in cancer therapy: Targeting the p53-MDM2\/MDMX interactions","volume":"11","author":"Munisamy","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.clml.2016.03.012","article-title":"High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome","volume":"16","author":"Han","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_123","first-page":"88","article-title":"MDM2 and MDMX: Alone and together in regulation of p53","volume":"1","author":"Shadfan","year":"2012","journal-title":"Transl. Cancer Res."},{"key":"ref_124","first-page":"69","article-title":"Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2","volume":"14","author":"Figueras","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"106489","DOI":"10.1016\/j.leukres.2020.106489","article-title":"Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1\/1b study","volume":"100","author":"Yee","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/fon-2020-0044","article-title":"MIRROS: A randomized, placebo-controlled, Phase III trial of cytarabine \u00b1 idasanutlin in relapsed or refractory acute myeloid leukemia","volume":"16","author":"Montesinos","year":"2020","journal-title":"Future Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2019-123711","article-title":"Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R\/R) AML Ineligible for Cytotoxic Chemotherapy","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","article-title":"Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53","volume":"27","author":"Saleh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","article-title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","volume":"10","author":"Carvajal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2018-99-118780","article-title":"Phase 1\/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, as Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed\/Refractory AML and Advanced MDS with TP53 Wild-Type","volume":"132","author":"Sallman","year":"2018","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., and Salaroli, A. (2022). New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073887"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting p53\u2013MDM2 interaction by small-molecule inhibitors: Learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"743006","DOI":"10.3389\/fonc.2021.743006","article-title":"Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14336\/AD.2020.0323","article-title":"Mechanism of Ferroptosis: A Potential Target for Cardiovascular Diseases Treatment","volume":"12","author":"Ju","year":"2021","journal-title":"Aging Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12935-021-02366-0","article-title":"Induction and application of ferroptosis in cancer therapy","volume":"22","author":"Nie","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellsig.2018.01.009","article-title":"Protein neddylation and its alterations in human cancers for targeted therapy","volume":"44","author":"Zhou","year":"2018","journal-title":"Cell Signal."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1089\/ars.2013.5795","article-title":"Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy","volume":"21","author":"Zhao","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"45263","DOI":"10.18632\/oncotarget.9481","article-title":"MLN4924 suppresses neddylation and induces cell cycle arrest, senescence and apoptosis in human osteosarcoma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbrc.2016.10.058","article-title":"An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924)","volume":"480","author":"Sumi","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3324\/haematol.2020.272609","article-title":"Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia","volume":"107","author":"Cojocari","year":"2021","journal-title":"Haematologica"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"20406207221112899","DOI":"10.1177\/20406207221112899","article-title":"The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): Hope or hype?","volume":"13","author":"Snow","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13578-021-00569-6","article-title":"Neddylation regulation of mitochondrial structure and functions","volume":"11","author":"Zhou","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine v.s. azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Girshova","year":"2022","journal-title":"Blood Adv."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/4995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:50:30Z","timestamp":1760143830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/4995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":143,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14204995"],"URL":"https:\/\/doi.org\/10.3390\/cancers14204995","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}